Puma Biotechnology (PBYI) Equity Ratio (2010 - 2026)

Puma Biotechnology has reported Equity Ratio for 17 years, with the latest figure at 0.67 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 34.63% year-over-year to 0.67; the trailing twelve-month figure through Mar 2026 stood at 0.67 (up 34.63% YoY), and the FY2025 full-year result was 0.6, up 39.54% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.67, up from 0.6 in the prior quarter.
• The five-year high for Equity Ratio was 0.67 in Q1 2026, with the low at 0.04 in Q1 2022.
• Historically, Equity Ratio has averaged 0.3 across 5 years, with a median of 0.24 in 2024.
• The largest YoY upside for Equity Ratio was 1001.41% in 2022 against a maximum downside of 43.63% in 2022.
• Puma Biotechnology's Equity Ratio stood at 0.1 in 2022, then soared by 138.24% to 0.23 in 2023, then jumped by 86.28% to 0.43 in 2024, then soared by 39.54% to 0.6 in 2025, then rose by 10.59% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.6 (Q4 2025), and 0.57 (Q3 2025), per Business Quant data.